9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is dev...
9 Meters Biopharma reported revenue of $0 for fiscal year 2022, and net income of -$43.77 million.
Figures from company filings; latest fiscal year ended December 31, 2022.
No profile data available.